Regulation of TGF-β1-induced pro-apoptotic signaling by growth factor receptors and extracellular matrix receptor integrins in the liver

Frontiers in Physiology

Volumn 2 OCT, Issue , 2011, Pages

  Ozaki, Iwata ^a   Hamajima, Hiroshi ^a   Matsuhashi, Sachiko ^a   Mizuta, Toshihiko ^a  

^a SAGA UNIVERSITY   (Japan)

Author keywords

Hepatocellular carcinoma; Integrins; Liver fibrosis; Smad; TGF 1

Indexed keywords

EID: 84866146034     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2011.00078     Document Type: Article

References (92)

1. Alam, N., Goel,H. L., Zarif,M. J., Butterfield, J. E., Perkins, H. M., Sansoucy, B. G., Sawyer, T. K., and Languino, L. R. (2007). The integrin-growth factor receptor duet. J. Cell. Physiol. 123, 649-653.
2. Baron, V., and Schwartz, M. (2000). Cell adhesion regulates ubiquitin-mediated degradation of the platelet-derived growth factor receptor beta. J. Biol. Chem. 275, 39318-39323.
3. Bedossa, P., Peltier, E., Terris, B., Franco, D., and Polynard, T. (1995). Transforming growth factor-beta 1(TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic and neoplas-tic human livers. Hepatology 21, 760-766.
4. Begum, N. A., Mori, M., Matsumata, T., Takenaka, K., Sugimachi, K., and Barnard, G. F. (1995). Differential display and integrin alpha 6 messenger RNA overexpression in hepa-tocellular carcinoma. Hepatology 22, 1447-1455.
5. Bergamini, C., Sgarra, C., Trerotoli, P., Lupo, L., Azzariti, A., Antonaci, S., and Giannelli G. (2007). Laminin-5 stimulates hepatocellular carcinoma growth through a different function of alpha6beta4 and alpha3beta1 integrins. Hepatology 46, 1801-1809.
6. Bhowmick, N. A., Ghiassi, M., Bakin, A., Aakre, M., Lundquist, C. A., Engel, M. E., Arteaga, C. L., and Moses, H. L. (2001). Transforming growth factor-beta1 mediates epithelial to mesenchymal trans-differentiation through a RhoA-dependent mechanism. Mol. Biol. Cell 12, 27-36.
7. Bierie, B., and Moses, H. L. (2006). TGFβ: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 6, 506-520.
8. Bottcher, R. T., Lange, A., and Fassler, R. (2009). How ILK and kindlins cooperate to orchestrate integrin signaling. Curr. Opin. Cell Biol. 21, 670-675.
9. Burch, M. L., Zheng, W., and Little, P. J. (2011). Smad linker phosphoryla-tion in the regulation of extracellular matrix synthesis. Cell Mol. Life Sci. 68, 97-107.
10. Cabodi, S., Moro, L., Bergatto, E., Boeri Erba, E., Di Stefano, P., Turco, E., Tarone, G., and Defilippi, P. (2004). Integrin regulation of epidermal growth factor (EGF) receptor and of EGF-dependent responses. Biochem. Soc. Trans. 32, 438-442.
11. Caja, L., Ortiz, C., Bertran, E., Murillo, M. M., Miró-Obradors, M. J., Pala-cios, E., and Fabregat, I. (2007). Differential intracellular signaling induced by TGF-beta in rat adult hepatocytes and hepatoma cells: implications in liver carcinogenesis. Cell. Signal. 19, 683-694.
12. Carloni, V., Mazzocca, A., Pantaleo, P., Cordella, C., Laffi, G., and Gentilini, P. (2001). The integrin, alpha6beta1, is necessary for the matrix-dependent activation of FAK and MAP kinase and the migration of human hepatocarcinoma cells. Hepatology 34, 42-49.
13. Couvelard, A., Scoazec, J.-Y., and Feld-mann, G. (1993). Expression of cell-cell and cell-matrix adhesion proteins by sinusoidal endothelial cells in the normal and cirrhotic human liver. Am. J. Pathol. 143, 738-752.
14. Cukierman, E., Pankov, R., Stevens, D. R., and Yamada, K. M. (2001). Taking cell-matrix adhesions to the third dimension. Science 294, 1708-1712.
15. Derynck, R., and Zhang, Y. (2003). Smad-dependent and Smad-independent pathways in TGF-beta family signaling. Nature 425, 577-584.
16. Desgrosellier, J. S., and Cheresh, D. A. (2010). Integrins in can-cer:biological implications and therapeutic opportunities. Nat. Rev. Cancer 10, 9-22.
17. El-Serag, H. B., and Rudolph, K. L. (2007). Hepatocellular carcinoma: epidemiology and molecular car-cinogenesis. Gastroenterology 132, 2557-2576.
18. Fabregat, I., Sánchez, A., Alvarez, A. M., Nakamura, T., and Benito, M. (1996). Epidermal growth factor, but not hepatocyte growth factor, suppresses the apoptosis induced by transforming growth factor-beta in fetal hepatocytes in primary culture. FEBS Lett. 384, 14-16.
19. Friedman, S. L. (2008). Mechanisms of hepatic fibrosis. Gastroenterology 134, 1665-1669.
20. Furukawa, F., Matsuzaki, K., Mori, S., Tahashi, Y., Yoshida, K., Sungano, Y., Yamagata, H., Matsushita, M., Seki, T., Inagaki, Y., Nishizawa, M., Fuji-sawa, J., and Inoue, K. (2003). p38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts. Hepatology 38, 879-889.
21. Giannelli, G., Bergamini, C., Fransvea, E., Marinosci, F., Quaranta, V., and Antonaci, S. (2001). Human hepa-tocellular carcinoma (HCC) cells require both alpha3beta1 integrin and matrix metalloproteinases activity for migration and invasion. Lab. Invest. 81, 613-627.
22. Giannelli, G., Mazzocca,A., Fransvea,E., Lahn, M., and Antonaci, S. (2011). Inhibiting TGF-β signaling in hepa-tocellular carcinoma. Biochem. Bio-phys. Acta 1815, 214-223.
23. Godoy, PL, Hengstler, J. G., Ilkavets, I., Bachmann, A., Muller, A., Tuschl, G., Mueller, S. O., and Dooley, S. (2009). Extracellular matrix modulates sensitivity of hepatocytes to fibroblastoid differentiation and transforming growth factor beta-induced apoptosis. Hepatology 49, 2031-2043.
24. Gómez-Lechón, M. J., Jover, R., Donato, T., Ponsoda, X., Rodriguez, C., Sten-zel, K. G., Klocke, R., Paul, D., Guil-lén, I., Bort, R., and Castell, J. V. (1998). Long-term expression of differentiated functions in hepatocytes cultured in three-dimensional collagen matrix. J. Cell. Physiol. 177, 553-562.
25. Hamajima, H., Ozaki, I., Zhang, H., Iwane, S., Kawaguchi, Y., Eguchi, Y., Matsuhashi, S., Mizuta, T., Mat-suzaki, K., Fujimoto, K. (2009). Modulation of the transforming growth factor-beta1-induced Smad phosphorylation by the extracellular matrix receptor beta1-integrin. Int. J. Oncol. 35, 1441-1447.
26. Hansen, L. K., and Albrecht, J. H. (1999). Regulation of the hepatocyte cell cycle by type I collagen matrix: role of cyclin D1. J. Cell Sci. 112, 2971-2981.
27. Hayashida, T. (2010). Integrins modulate cellular fibrogenesis at multiple levels; regulationof TGF-β signaling. Endocr. Metab. Immune Disord. Drug Ta r g e t s 10, 302-319.
28. Hehlgans, S., Haase, M., and Cordes, N. (2007). Signaling via integrins: Implications for cell survival and anticancer strategies. Biochem. Bio-phys. Acta 1775, 163-180.
29. Heldin, C. H., Miyazono, K., and ten Dijke, P. (1997). TGF-β signaling from cell membrane to nucleus through SMAD proteins. Nature 390, 465-471.
30. Hynes, R. O. (2002). Integrins: bidirectional, allosteric signaling machines. Cell 110, 673-387.
31. Inagaki, Y., and Okazaki, I. (2007). Emerging insights into transforming growth factor β Smad signaling in hepatic fibrogenesis. Gut 56, 284-292.
32. Ito, N., Kawata, S., Tamura, S., Takaishi, K., Shirai, Y., Kiso, S., Yabuuchi, I., Matsuda, Y., Nishioka, M., and Tarui, S. (1991). Elevated levels of transforming growth factor beta messenger RNA and its polypeptide in human hepatocel-lular carcinoma. Cancer Res. 51, 4080-4083.
33. Ivaska, J., and Heino, J. (2010). Interplay between cell adhesion and growth factor receptors: from the plasma membrane to the endosomes. Cell. Tissue Res. 339, 111-120.
34. Jang, C. W., Chen, C. H., Chen, C. C., Chen, J. Y., Su, Y. H., and Chen, R. H. (2002). TGF-beta induces apopto-sis through Smad-mediated expression of DAP-kinase. Nat. Cell Biol. 4, 51-58.
35. Jung, K. S., Kim, S. U., Ahn, S. H., Park, Y. N., Kim, do Y., Park, J. Y., Chon, C. Y., Choi, E. H., and Han, K. H. (2011). Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology 53, 885-894.
36. Kamaraju, A. K., and Roberts, A. B. (2005). Role of Rho/ROCK and p38 MAP kinase pathways in transforming growth factor-β-mediated Smad-dependent growth inhibition of human breast carcinoma cells in vivo. J. Biol. Chem. 280, 1024-1036.
37. Ke, A. W., Shi, G. M., Zhou, J., Huang, X. Y., Shi, Y. H., Ding, Z. B., Wang, X. Y., Devbhandari, R. P., and Fan, J. (2011). CD151 amplifies signaling by integrin α6β1 to PI3K and induces the epithelial-mesenchymal transition in HCC Cells. Gastroen-terology 140, 1629-1641.
38. Kretzschmar, M., Doody, J., Timokhina, I., and Massagué, J. (1999). A mechanism of repression of TGF-β/Smad signaling by oncogenic Ras. Genes Dev. 13, 804-816.
39. Lai,K. K., Shang, S., Lohia, N., Booth, G. C., Masse, D. J., Fausto, N., Campbell, J. S., and Beretta, L. (2011). Extracellular matrix dynamics in hepatocarcinogenesis: a comparative proteomics study of PDGFC transgenic and Pten null mouse models. PLoS Genet. 7, e1002147. doi:10.1371/journal.pgen.1002147
40. Levine, D., Rockey, D. C., Milner, T. A., Breuss, T., Fallon, J. T., and Schnapp, L. M. (2000). Expression of α8β1 integrin during pulmonary and hepatic fibrosis. Am. J. Pathol. 156, 1927-1935.
41. Li, J., Tan, H., Dong, X., Xu, Z., Shi, C., Han, X., Jiang, H., Krissansen, G. W., and Sun, X. (2007). Anti-sense integrin alphaV and beta3 gene therapy suppresses subcuta-neously implanted hepatocellular carcinomas. Dig. Liver Dis. 39, 557-565.
42. Lin, J. K., and Chou, C. K. (1992). In vitro apoptosis in the human hepatoma cell line induced by transforming growth factor beta 1. Cancer Res. 52, 385-388.
43. LIovet, J. M., Burroughs, A., and Bruix, J. (2003). Hepatocellular carcinoma. Lancet 362, 1907-1917.
44. Margadant, C., and Sonnenberg, A. (2010). Integrin-TGF-β crosstalk in fibrosis, cancer and wound healing. EMBO Rep. 11, 97-105.
45. Massague, J. (2008). TGF-β in cancer. Cell 134: 215-230.
46. Massague, J., Seonae, J., and Wotton, D. (2005). Smad transcription factors. Genes Dev. 19, 2783-2810.
47. Masuzaki, R., Tateishi, R., Yoshida, H., Goto, E., Sato, T., Ohki, T., Ima-mura, J., Goto, T., Kanai, F., Kato, N., Ikeda, H., Shiina, S., Kawabe, T., and Omata, M. (2009). Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology 49, 1954-1961.
48. Matsuura, I., Denissova, N. G., Wang, G., He, D., Long, J., and Liu, F. (2004). Cyclin-dependent kinases regulated the antiproliferative function of Smads. Nature 430, 226-231.
49. Matsuzaki, K. (2011). Smad phospho-isoform signals in acute and chronic liver injury: similarities and differences between epithelial and mes-enchymal cells. Cell Tissue Res. doi: 10.1007/s00441-011-1178-6. [Epub ahead of print].
50. Matsuzaki, K., Murata, M., Yoshida, K., Sekimoto, G., Uemura, Y., Sakaida, N., Kaibori, M., Kamiyama, Y., Nishizawa, M., Fujisawa, J., Okazaki, K., and Seki, T. (2007). Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology 46, 48-57.
51. Millard, M., Odde, S., and Neamati, N. (2011). Integrin targeted therapeutics. Theranostics 1, 154-188.
52. Mori, S., Matsuzaki, K., Yoshida, K., Furukawa, F., Tahashi, Y., Yamagata, H., Sekimoto, G., Seki, T., Matsui, H., Nishizawa, M., Fujisawa, J., and Okazaki, K. (2004). TGF-beta and HGF transmit the signals through JNK-dependent Smad2/3 phospho-rylation at linker regions. Oncogene 23, 7416-7429.
53. Moro, L., Dolce, L., Cabodi, S., Bergatto, E., Boeri-Erba, E., Smeriglio, M., Turco, E., Retta, S. F., Giuffrida, M. G., Venturino, M., Godovac-Zimmermann, J., Conti, A., Schae-fer, E., Beguinot, L., Tacchetti, C., Gaggini, P., Silengo, L., Tarone, G., and Defilippi, P. (2002). Integrin-induced epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phos-phorylation of specific EGF receptor tyrosines. J. Biol. Chem. 277, 9405-9414.
54. Moses, H. L., Yang, E. Y., and Pieten-pol, J. A. (1990). TGF-β stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 63, 245-247.
55. Moustakas,A.,and Heldin,C.H.(2005). Non-Smad TGF-beta signals. J. Cell Sci. 118, 3573-3584.
56. Murata, M., Matsuzaki, K., Yoshida, K., Sekimoto, G., Tahashi, Y., Mori, S., Uemura, Y., Sakaida, N., Fujisawa, J., Seki, T., Kobayashi, K., Yokote, K., Koike, K, and Okazaki K. (2009). Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B. Hepatology 49, 1203-1217.
57. Murillo, M. M., del Castillo, G., Sánchez, A., Fernández, M., and Fabregat, I. (2005). Involvement of EGF receptor and c-Src in the survival signals induced by TGF-beta1 in hepatocytes. Oncogene 24, 4580-4587.
58. Nagata, H., Hatano, E., Tada, M., Murata, M., Kitamura, K., Asechi, H., Narita, M., Tamaki, N., Yagi, S., Ikai, I., Matsuzaki, K., and Uemoto, S. (2009). Inhibition of c-Jun NH2-terminal kinase switches Smad3 signaling from oncogenesisi to tumor-suppression in rat hepa-tocellular carcinoma. Hepatology 49, 1944-1953.
59. Nakashima, M., Hamajima, H., Xia, J., Iwane, S., Kwaguchi, Y., Eguchi, Y., Mizuta, T., Fujimoto, K., Ozaki, I., and Matsuhashi, S. (2010). Regulation of tumor suppressor PDCD4 by novel protein kinase C iso-forms. Biochim. Biophys. Acta 1803, 1020-1027.
60. Oberhammer, F. A., Pavelka, M., Sharma, S., Tiefenbacher, R., Pur-chio, A. F., Bursch, W., and Shulte-Hermann, R. (1992). Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor beta 1. Proc. Natl. Acad. Sci. U.S.A. 89, 5408-5412.
61. Okuda, K. (2000). Hepatocellular carcinoma. J. Hepatol. 32, 225-237.
62. Ozaki, I., Yamamoto, K., Mizuta, T., Kajihara, S., Fukushima, N., Setoguchi, Y., Morito, F., and Sakai, T. (1998). Differential expression of laminin receptors in human hepato-cellular carcinoma. Gut 43, 837-842.
63. Perlman, R., Schiemann, W. P., Brooks, M. W., Lodish, H. F., and Weinberg, R. A. (2001). TGF-beta-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation. Nat. Cell Biol. 3, 708-714.
64. Petritsch, C., Beug, H., Balmain, A., and Oft, M. (2000). TGF-beta inhibits p70 S6 kinase via protein phos-phatase 2A to induce G(1) arrest. Genes Dev. 14, 3093-3101.
65. Reginato, M. J., Mills,K. R., Paulus, J. K., Lynch, D. K., Sgroi, D. C., Debnath, J., Muthuswamy, S. K., and Brugge, J. S. (2003). Integrins and EGFR coor-dinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat. Cell Biol. 5, 733-740.
66. Sakaida, I., Hironaka, K., Uchida, K., Suzuki, C., Kayano, K., and Okita, K. (1998). Fibrosis accelerates the development of enzyme-altered lesions in rat liver. Hepatology 28, 1247-1252.
67. Schrader, J., Gordon-Walker, T. T., Aucott, R. L., van Deemter, M., Quaas, A., Walsh, S., Benten, D., Forbes, S. J., Wells, R. G., and Iredale, J. P. (2011). Matrix stiffness modulates proliferation, chemotherapeu-tic response, and dormancy in hepa-tocellular carcinoma cells. Hepatol-ogy 53, 1192-1205.
68. Senturk, S., Mumcuoglu, M., Gursoy-Yuzugullu, O., Cingoz, B., Akcali, K. C., and Ozturk, M. (2010). Transforming growth factor-beta induces senescence in hepatocellular carcinoma cells and inhibits tumor growth. Hepatology 52, 966-974.
69. Sethi, T., Rintoul, R. C., Moore, S. M., MacKinnon, A. C., Salter, D., Choo, C., Chilvers, E. R., Dransfield, I., Donnelly, S. C., Strieter, R., Haslett, C. (1999). Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med. 5, 662-668.
70. Shiota, G., Rhoads, D. B., Wang, T. C., Nakamura, T., and Schmidt, E. V. (1992). Hepatocyte growth factor inhibits growth of hepatocellular carcinoma cells. Proc. Natl. Acad. Sci. U.S.A. 89, 373-377.
71. Siegel, P. M., and Massague, J. (2003). Cytostatic and apoptotic actions of TGF-betainhomeostasisand cancer. Nat. Rev. Cancer 3, 807-821.
72. Sugano, Y., Matsuzaki, K., Tahashi, Y., Furukawa, F., Mori, S., Yamagata, H., Yoshida, K., Matsushita, M., Nishizawa, M., Fujisawa, J., and Inoue, K. (2003). Distortion of autocrine transforming growth factor b signal acceleratesmalignant potential by enhancing cell growth as well as PAI-1 and VEGF production in human hepatocellular carcinoma cells. Oncogene 22, 2309-2321.
73. Tajima, H., Matsumoto, K., and Nakamura, T. (1991). Hepatocyte growth factor has potent anti-proliferative activity in various tumor cell lines. FEBS Lett. 291, 229-232.
74. Tilghman, R. W., Cowan, C. R., Mih, J. D., Koryakina, Y., Gioeli, D., Slack-Davis, J. K., Blackman, B. R., Tschumperlin, D. J., and Parsons, J. T. (2010). Matrix rigidity regulates cancer cell growth and cellular phenotype. PLoS ONE 5, e12905. doi:10.1371/journal.pone.0012905
75. Torimura, T., Ueno, T., Kin, M., Harada, R., Nakamura, T., Kawaguchi, T., Harada, M., Kumashiro, R., Watanabe, H., Avraham, R., and Sata, M. (2001). Autocrine motility factor enhances hepatoma cell invasion across the basement membrane through activation of beta1 inte-grins. Hepatology 34, 62-71.
76. Tsai, J. F., Jeng, J. E., Chuang, L. Y., Yang, M. L., Ho, M. S., Chang, W. Y., Hsieh. M. Y., Lin, Z. Y, and Tsai, J. H. (1997). Elevated urinary transforming growth factor-beta 1 level as a tumor marker and predictor of poor survival in cirrhotic hepato-cellular carcinoma. Br. J. Cancer 76, 244-50.
77. Tsukuma, H., Hiyama, T., Tanaka, S., Nakao, M., Yabuuchi, T., Kitamura, T., Nakanishi, K., Fujimoto, I., Inoue, A., Yamazaki, H., and Kawashima, T. (1993). Risk factor for hepatocellu-lar carcinoma among patients with chronic liver disease. N. Engl. J. Med. 328, 1797-1801.
78. Volpes, R., van den Oord, J. J., and Desmet, V. J. (1991). Distribution of the VLA family of integrins in normal and pathological human liver tissue. Gastroenterology 101, 200-206.
79. Volpes, R., van den Oord, J. J., and Desmet, V. J. (1993). Integrins as differential cell lineage markers of primary liver tumors. Am. J. Pathol. 142, 1483-1492.
80. Wang, R., Ferrell, L. D., Faouzi, S., Maher, J. J., and Bishop, J. M. (2001). Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J. Cell Biol. 153, 1023-1034.
81. Wells, R. G. (2008). The role of matrix stiffness in regulating cell behavior. Hepatology 47, 1394-1400.
82. Wrighton, K. H., Lin, X., and Fen, X. (2009). Phospho-control of TGF-β superfamily signaling. Cell Res. 19, 8-20.
83. Yang, Y. A., Zhang, G. M., Feigenbaum, L., and Zhang, Y. E. (2006). Smad3 reduces susceptibility to hepatocar-cinoma by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2. Cancer Cell 9, 445-457.
84. Yi, J. Y., Shin, I., and Arteaga, C. L. (2005). Type I transforming growth factor-beta receptor binds to and activates phosphatidylinos-itol 3-kinase. J. Biol. Chem. 280, 10870-10876.
85. Yoo, J., Ghiassi, M., Jirmanova, L., Balliet, A. G., Hoffman, B., Fornace, A. J. Jr., Liebermann, D. A., Bottinger, E. P., and Roberts, A. B. (2003). Transforming growth factor-beta-induced apoptosis is mediated by Smad-dependent expression of GADD45β through p38 activation. J. Biol. Chem. 278, 43001-43007.
86. Yoshida, H., Shiratori, Y., Moriyama, M., Arakawa, Y., Ide, T., Sata, M., Inoue, O., Yano, M., Tanaka, M., Fujiyama, S., Nishiguchi, S., Kuroki, T., Imazeki, F.,Yokosuka, O., Kinoyama, S., Yamada, G., and Omata, M. (1999). Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and non-cirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by inter-feron therapy. Ann. Intern. Med. 131, 174-181.
87. Yoshida, K., Matsuzaki, K., Mori, S., Tahashi, Y., Yamagata, H., Furukawa, F., Seki, T., Nishizawa, M., Fujisawa, J., and Okazaki, K. (2005). Transforming growth factor-beta and platelet-derived growth factor signal via c-Jun N-terminal kinase-dependent Smad2/3 phosphoryla-tion in rat hepatic stellate cells after acute liver injury. Am. J. Pathol. 166, 1029-1039.
88. Zhang, H., Ozaki, I., Mizuta, T., Hamajima, H., Yasutake, T., Eguchi, Y., Ideguchi, H., Yamamoto, K., and Matsuhashi, S. (2006). Involvement of programmed cell death 4 in transforming growth factor-beta1-induced apoptosis in human hepatocellular carcinoma. Oncogene 25, 6101-6012.
89. Zhang, H., Ozaki, I., Mizuta, T., Matsuhashi, S., Yoshimura, T., Hisatomi, A., Tadano, J., Sakai, T., and Yamamoto K. (2002). Beta 1-integrin protects hepatoma cells from chemotherapy induced apop-tosis via a mitogen-activated protein kinase dependent pathway. Cancer 95, 896-906.
90. Zhang, H., Ozaki, I., Mizuta, T., Yoshimura, T., Matsuhashi, S., Eguchi, Y., Yasutake, T., Hisatomi, A., Sakai, T., and Yamamoto, K. (2004). Transforming growth factor-beta 1-induced apoptosis is blocked by beta 1-integrin- mediated mitogen-activated protein kinase activation in human hepatoma cells. Cancer Sci. 95, 878-886.
91. Zhang, H., Ozaki, I., Mizuta, T., Yoshimura, T., Matsuhashi, S., Hisatomi, A., Tadano, J., Sakai, T., and Yamamoto, K. (2003). Mechanism of beta 1-integrin-mediated hepatoma cell growth involves p27 and S-phase kinase-associated protein 2. Hepatology 38, 305-313.
92. Zhao, G., Cui, J., Qin, Q., Zhang, J., Liu, L., Deng, S., Wu, C., Yang, M., Li, S., and Wang, C. (2010). Mechanical stiffness of liver tissues in relation to integrin β1 expression may influence the development of hepatic cirrhosis and hepatocellular carcinoma. J. Surg. Oncol. 102, 482-489.